tislelizumab

Overview

Tislelizumab (BGB-A317) is a humanized monoclonal antibody that targets programmed death 1 (PD-1), a key immune checkpoint receptor expressed on T cells. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, tislelizumab restores antitumor immune activity that cancer cells exploit to evade immune surveillance. Engineered with a modified Fc region to minimize Fc gamma receptor binding on macrophages — a mechanism thought to reduce antibody-dependent cellular phagocytosis of T cells — tislelizumab is designed to preserve effector T cell function more effectively than earlier generation PD-1 inhibitors. Developed by BeiGene, the drug has received regulatory approval in China and select global markets for multiple indications including non-small cell lung cancer, hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma (ESCC).

As a PD-1 checkpoint inhibitor, tislelizumab belongs to the broader class of immune oncology agents that have transformed the treatment landscape for solid tumors over the past decade. Its clinical development has expanded across gastrointestinal malignancies, thoracic cancers, and combination strategies with chemotherapy, radiotherapy, and targeted biologics — reflecting a growing emphasis on harnessing immunotherapy within multimodal treatment regimens.

Recent Publications Focus

Below is a summary of the newest research publications targeting tislelizumab (sorted by publication date).

Recent studies have continued to evaluate tislelizumab across multiple solid tumors, with a strong emphasis on lung and esophageal cancers. A transportability analysis of the RATIONALE-315, RATIONALE-303, and RATIONALE-312 trials suggested that efficacy findings for tislelizumab in perioperative non-small cell lung cancer (NSCLC), advanced NSCLC, and extensive-stage small cell lung cancer (ES-SCLC) were broadly consistent when projected to European-like populations, with predicted outcomes favoring tislelizumab over control under the study’s assumptions. In advanced squamous NSCLC, the RATIONALE-307 program also remained a focus, including work examining how patient-reported outcomes such as global health status/quality of life and symptoms like cough and dyspnea related to overall survival. In the HARMONi-6 setting, tislelizumab plus chemotherapy served as the comparator arm in a phase 3 trial of ivonescimab plus chemotherapy, and the report described a prespecified interim overall survival analysis. Separately, a phase II study in advanced pulmonary sarcomatoid carcinoma assessed tislelizumab combined with anlotinib as first-line therapy.

Tislelizumab has also been studied in several perioperative and multimodal treatment strategies for esophageal squamous cell carcinoma (ESCC). The RATIONALE-213 final analysis evaluated PET/CT-guided neoadjuvant tislelizumab plus chemotherapy or chemoradiotherapy in resectable ESCC, while another multicenter randomized phase II trial (EC-CRT-002) examined adding tislelizumab to induction chemotherapy and concurrent chemoradiotherapy, with or without maintenance immunotherapy, in unresectable locally advanced ESCC. In advanced oesophageal squamous cell carcinoma, a value-based pricing analysis modeled the cost-effectiveness of tislelizumab plus chemotherapy versus chemotherapy alone from the US payer perspective. Tislelizumab also appeared in a phase 2 gastroesophageal cancer study of zanidatamab with and without tislelizumab, where the combination with chemotherapy showed encouraging efficacy and safety in HER2-positive gastroesophageal adenocarcinoma.

Beyond thoracic and upper gastrointestinal malignancies, newer publications explored tislelizumab in ovarian and bladder cancer. In the exploratory NAIVE trial, neoadjuvant platinum-based chemotherapy plus tislelizumab was compared with chemotherapy alone in FIGO IIIC-IV epithelial ovarian cancer, showing numerically longer progression-free survival, higher 1-year and 2-year PFS rates, improved response measures, and manageable immune-related adverse events, although the primary efficacy comparison was not statistically significant. Immune profiling in that study suggested a potential role for the CXCL13+Th1-GC B-cell-tertiary lymphoid structure axis as a biomarker and mechanistic driver of response. Another report in very high-risk nonmuscle-invasive bladder cancer described MRI radiomic phenotypes intended to stratify response and define immune states in patients treated with tislelizumab plus nanoparticle albumin-bound paclitaxel, although the abstract provided only the study objective.

Development work has also expanded beyond efficacy studies. A model-informed phase 1 pharmacokinetic study evaluated a subcutaneous formulation of tislelizumab in patients with cancer, comparing thigh and abdominal administration with intravenous dosing in treatment-naïve locally advanced or metastatic NSCLC. Population pharmacokinetic modeling and simulations supported subcutaneous 300 mg every 3 weeks administered in the thigh as providing exposure comparable to intravenous 200 mg every 3 weeks, with greater bioavailability and lower variability than abdominal administration. Overall, these publications show tislelizumab being investigated both as a backbone immunotherapy in combination regimens and as a candidate for new delivery approaches, with emerging data spanning efficacy, biomarker development, transportability, and pharmacokinetic optimization.

Method PMIDs

• [PMID 42243329]

Target PMIDs

• [PMID 41770095]
• [PMID 41894181]
• [PMID 41962116]
• [PMID 42047833]
• [PMID 42202319]
• [PMID 42203284]
• [PMID 42218899]
• [PMID 42319531]
• [PMID 42337921]
• [PMID 42339693]
• [PMID 42399240]
• [PMID 42412689]